US & Europe Gene Editing Market
Published On: Aug 2023
Published On: Aug 2023
According to our latest study on “US & EU Gene Editing Market Forecast to 2028 – COVID-19 Impact and Global Analysis – by technology, product and services, application, end user, and geography” the market is projected to reach US$ 15,052.92 million by 2030 from US$ 3,955.09 million in 2022; it is expected to grow at a CAGR of 18.2% from 2022 to 2030. The report highlights the key factors driving the market growth and prominent players with their developments in the market. The US & EU gene editing market growth is attributed to some key driving factors such as rise in the prevalence of cancer and other genetic disorders and continuous technological advancements in gene editing tools are driving the US & EU gene editing market. However, the high cost of production of gene editing methods may hinder US & EU gene editing market growth
Gene editing tools have been used to combat COVID-19. For instance, In October 2021, researchers from the Georgia Institute of Technology and Emory University developed gene-edited enzymes that attack the polymerase chains of the virus to disable it from making more RNA replicate itself, thereby allowing the patient to recover. This new treatment is also being designed to be delivered to the lungs using a nebulizer for better accessibility and easier administration by the patient.
Based on the technology is segmented into CRISPR, TALEN, antisense, Zinc Finger Nucleases (ZFNs), and others. In 2022, the CRISPR segment held the largest share of the US & EU gene editing market. Moreover, the same segment is also expected to grow at the fastest rate during the coming years. Based on the products and services is segmented into reagents and consumables, instruments, and others. In 2022, the reagents and consumables segment held the largest share of the US & EU gene editing market. Moreover, the same segment is also expected to grow at the fastest rate during the coming years. Based on the application is segmented into cell line engineering, genetic engineering, diagnostic application, drug discovery, and others. In 2022, the cell line engineering segment held the largest share of the market. Moreover, the same segment is also expected to grow at the fastest rate during the coming years. Based on the end user is segmented into pharmaceutical & biotechnology companies, academic and research institutes, contract research organization (CROs), others. In 2022, the pharmaceutical & biotechnology companies segment held the largest share of the US & EU gene editing market. However, the academic and research institutes segment is expected to grow at the fastest rate during the coming years.
Thermo Fisher Scientific Inc.; Merck KGaA; Lonza; PerkinElmer.; Integrated DNA Technologies; GenScript; New England Biolabs; Eurofins Scientific; CRISPR Therapeutics; Editas Medicine; and ElevateBio are among the leading companies operating in the US & EU gene editing market.
Source: Business Market Insights Analysis
Contact Us
Contact Person: Sameer Joshi
Phone: +1-646-491-9876
Email Id: sales@businessmarketinsights.com
Office No. 1011, First floor, Farena Corporate Park, Magarpatta-Mundhwa road, Pune - 411028, Maharashtra, India
US:+16467917070
sales@businessmarketinsights.com
